What’s Up with Molly (MDMA) After the Executive Order?
Some likely scenarios in FDA approval process for the empathogen MDMA in PTSD.
Updated May 18, 2026 | Reviewed by Hara Estroff Marano
Few compounds better illustrate the tension between therapeutic promise, regulatory skepticism, abuse liability, and political momentum surrounding post- traumatic stress disorder ( PTSD ) than the drug MDMA, a drug that acts as both a stimulant and a hallucinogen (empathogen and an entactogen) known by the street names Ecstasy and Molly. At one time primarily associated with rave culture, it is used to change energy, mood, empathy, distort time perception, and enhance the enjoyment of tactile experiences and pleasure. MDMA continues to be studied as a potentially transformative psychiatric intervention for PTSD.
The recent presidential Executive Order on psychedelic therapies did not legalize MDMA, nor did it bypass FDA authority. Instead, it may have shifted where the future of psychedelic psychiatry will ultimately be decided. The Executive Order apparently repositions the Department of Veterans Affairs (VA) and the Department of Defense (DoD) as major research infrastructures for psychedelic medicine.
This means that the future of MDMA-assisted therapy may depend less on advocacy groups and much more on whether federally supervised studies on veterans and active-duty military personnel demonstrate durable, standardized, and clinically meaningful outcomes.
From “Molly” to Medicine
Historically, MDMA referred to pressed tablets sold in dance clubs, while “Molly” became shorthand for supposedly pure crystalline MDMA. In reality, however, forensic analyses have repeatedly shown that illicit products sold as MDMA are often adulterated with methamphetamine, synthetic cathinones, ketamine analogs, caffeine, cocaine, or fentanyl.
MDMA became widely known as the “love drug” because of its empathogenic effects. Users frequently reported increased emotional openness , heightened interpersonal trust, reduced defensiveness, and stronger feelings of emotional connection. These same effects also raised concerns regarding emotional suggestibility, compromised judgment, and vulnerability to exploitation.
This double identity —as a possible therapeutic agent and a recreational drug of abuse—continues shaping MDMA’s regulatory history.
As a recent editorial in the journal Lancet (2026) observed, the principal challenge facing psychedelic psychiatry is to “separate hope firmly from hype.” The editorial noted that psychedelic-assisted therapy trials remain difficult to blind effectively (or to hide what they are, so subjects can’t tell whether they took the study drug or the placebo ). Importantly, however, the editorial characterized many FDA concerns regarding MDMA-assisted psychotherapy as “remediable issues".
Why the FDA Rejected MDMA in 2024
Early randomized trials demonstrated unusually large effect sizes in patients with severe and treatment-resistant PTSD, including veterans, first responders, and survivors of chronic trauma. Phase-2 and Phase-3 studies showed substantial reductions in Clinician-Administered PTSD Scale (CAPS) scores, and the pivotal MAPP1 trial published in Nature Medicine in 2021 became a landmark for psychedelic psychiatry.
Despite this impetus, the FDA declined to approve MDMA-assisted therapy in 2024.
The FDA was less concerned with MDMA's positive effects in PTSD but on methodological weaknesses, compromised blinding, psychotherapy standardization issues, safety-reporting limitations, therapist misconduct allegations, data integrity, and the durability and overall benefit–risk profile of MDMA-assisted therapy.
Why Israeli PTSD Research Matters
Israel provides an important perspective through which to understand the next phase of MDMA research. Israeli psychiatrists and trauma specialists have extensive experience treating combat veterans, terrorism survivors, and civilians exposed to chronic threat environments and have reported on treatments and outcomes from the Yom Kippur War. Israeli military psychiatry emphasizes immediate field assessment and proximity-based intervention following traumatic exposure, with the goal of restoring function early and reducing progression to PTSD.
Israeli researchers helped conduct some of the early studies of MDMA-assisted therapy. However, even in Israel, MDMA treatment is still tightly controlled and used mainly for patients with severe PTSD who have not improved with standard treatments.
What makes the Israeli experience especially important is its emphasis on functional restoration rather than symptom reduction alone. Israeli military psychiatry traditionally focuses on resilience , operational performance, interpersonal cohesion, immediate field intervention after traumatic exposure, and rapid return to military role/function. Israeli experts use MDMA as a catalyst to temporarily reduce fear and defensiveness sufficiently to improve engagement with psychotherapy.
Why VA and DoD Studies May Become Decisive
After the president’s Executive Order, many believe the most consequential studies in the United States will likely occur within the VA and DoD systems. In contrast to smaller civilian psychedelic trials, the federal systems provide centralized medical records, standardized psychotherapy pathways, long-term follow-up, neurocognitive assessment, suicidality monitoring, and highly characterized trauma populations.
Importantly, military psychiatry evaluates outcomes differently from many civilian programs. The central question is not simply whether patients begin to feel better but whether they can function safely and effectively under high-stress military working conditions. Improved function is important, but resuming normal functioning is better.
Future Pentagon-backed MDMA studies are expected to examine outcomes such as emotional control under stress, sleep restoration, cognitive performance, suicide-risk reduction, interpersonal functioning, return-to-duty capacity, and durability of benefit after repeated stress exposure.
These trials may also address several methodological weaknesses identified during the FDA review process. Standardized therapist training, tighter protocol enforcement, centralized adverse-event reporting, biomarker integration, and prolonged longitudinal follow-up may ultimately generate evidence that regulators view as more rigorous and reproducible.
Separating Psychedelic Medicine from the Illicit MDMA Market
The Executive Order does not legalize illicit MDMA, nor does it diminish ongoing public-health concerns. The 2025 Drug Enforcement Administration's National Drug Threat Assessment categorizes MDMA usage as relatively low compared to drugs like fentanyl, methamphetamine, and cocaine. However, MDMA remains widely abused by adolescents and young adults, produced by clandestine synthetic labs, and shipped to the U.S by transnational trafficking networks. The DEA warns that many substances sold as “Ecstasy” contain little or no MDMA at all.
The distinction is critical. Pharmaceutical MDMA research involves verified purity, known dosing, medical screening, and supervised administration. Illicit Molly or Ecstasy, by contrast, frequently reflects an unpredictable clandestine market with unknown pharmacologic composition.
The Future of Psychedelic Psychiatry
Psychedelic psychiatry is increasingly moving away from countercultural enthusiasm and toward large-scale federal research systems, randomized clinical trials, uniform protocols, formal regulatory scrutiny, biomarker-driven neuroscience , and longitudinal outcome analysis.
As The Lancet editorial emphasized, the challenge now is to align psychedelic psychiatry with scientific thoroughness. The future of MDMA-assisted psychotherapy will not be determined primarily by politics , media enthusiasm, or advocacy alone. Instead, it will depend on whether researchers can demonstrate reproducible efficacy, durable safety, transparent methodology, and clinically significant improvements in veterans and active-duty personnel under rigorous scientific assessment.
Williams ZJ, Barnett H, Szigeti B. Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions: A Systematic Review and Meta-Analysis. JAMA Psychiatry . 2026;83(5):461–468. doi:10.1001/jamapsychiatry.2025.4809
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439-452. doi:10.1177/0269881110378371
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after MDMA-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol . 2013;27(1):28-39. doi:10.1177/0269881112456611
Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013 Jan;27(1):40-52. doi: 10.1177/0269881112464827. Epub 2012 Oct 31. PMID: 23118021.
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1. PMID: 29728331.
Neria Y, Solomon Z, Ginzburg K, Dekel R, Enoch D, Ohry A. Posttraumatic residues of captivity: a follow-up of Israeli ex-prisoners of war. J Clin Psychiatry . 2000 Jan;61(1):39-46. doi: 10.4088/jcp.v61n0110. PMID: 10695645.
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PMID: 33972795; PMCID: PMC8205851.
Mitchell JM, Ot'alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, Paleos C, Nicholas CR, Quevedo S, Balliett B, Hamilton S, Mithoefer M, Kleiman S, Parker-Guilbert K, Tzarfaty K, Harrison C, de Boer A, Doblin R, Yazar-Klosinski B; MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med . 2023 Oct;29(10):2473-2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14. Erratum in: Nat Med. 2024 Nov;30(11):3382. doi: 10.1038/s41591-024-03331-w. PMID: 37709999; PMCID: PMC10579091.
Shahrour G, Sohail K, Elrais S, Khan MH, Javeid J, Samdani K, Mansoor H, Hussain SI, Sharma D, Ehsan M, Nashwan AJ. MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs). Neuropsychopharmacol Rep. 2024 Dec;44(4):672-681. doi: 10.1002/npr2.12485. Epub 2024 Oct 9. PMID: 39381877; PMCID: PMC11609750.
Colcott J, Guerin AA, Carter O, Meikle S, Bedi G. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology . 2024 Jul;49(8):1208-1226. doi: 10.1038/s41386-024-01865-8. Epub 2024 Apr 23. PMID: 38654146; PMCID: PMC11224236.
Solomon Z, Mikulincer M. Trajectories of PTSD: a 20-year longitudinal study. Am J Psychiatry . 2006 Apr;163(4):659-66. doi: 10.1176/ajp.2006.163.4.659. PMID: 16585441.
This article is part of the Bringwise Psychology Journal — daily insights on human behavior, mental health, and personal growth.